Nicholson Nur
Chief Technical Officer
Nicholson Nur has filed 5 SEC Form 4 filings (16 transaction rows) across 1 company, with disclosures dating back to 2026. 5 of those filings fall inside the rolling window. Most recent filing: May 14, 2026.
On the most recent filing, Nicholson Nur is listed as Chief Technical Officer at Apellis Pharmaceuticals, Inc. Inside the rolling window, Nicholson Nur reported no open-market purchases and 3 open-market sales totaling $270K in APLS. The largest disclosed transaction in the window is a sale of 7,725 APLS shares on Jan 22, 2026, worth $168K.
Companies traded
Other insiders at APLS
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$270K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Nicholson Nur made?
Nicholson Nur has filed 5 SEC Form 4 filings (16 transaction rows) across 1 company since 2026.
Which companies does Nicholson Nur trade?
Nicholson Nur has filed SEC Form 4 disclosures for 1 company, including APLS.
When was Nicholson Nur's most recent SEC Form 4 filing?
Nicholson Nur's most recent SEC Form 4 filing on Tracefour is dated May 14, 2026.
What is Nicholson Nur's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Nicholson Nur is listed as Chief Technical Officer.
What is Nicholson Nur's total buy and sell value in the current window?
Inside the rolling retention window, Nicholson Nur bought $0 and sold $270K based on SEC Form 4 filings.
What was Nicholson Nur's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 7,725 APLS shares on 2026-01-22, worth $168K, per SEC Form 4 filings.